Verrica Pharmaceuticals Inc. (VRCA) – What Are Investment Firms Thinking About This Stock?

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have received an average recommendation of “Hold” from the five analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $12.67.

VRCA has been the topic of several research reports. Wall Street Zen lowered Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, October 13th. Finally, Lake Street Capital started coverage on Verrica Pharmaceuticals in a report on Thursday, August 27th. They issued a “buy” rating and a $9.00 target price for the company.

Verrica Pharmaceuticals Stock Up 3.2%

Shares of NASDAQ VRCA opened at $3.19 on Tuesday. The business has a 50-day moving average of $4.24 and a two-hundred day moving average of $5.51. The company has a market capitalization of $54.80 million, a price-to-earnings ratio of -1.91 and a beta of 1.69. Verrica Pharmaceuticals has a 1 year low of $3.08 and a 1 year high of $9.82. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.45 and a quick ratio of 1.33.

Institutional Investors Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its position in Verrica Pharmaceuticals stock. Fifth Third Bancorp raised its position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 100.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 28,000 shares of the company’s stock after buying an additional 14,000 shares during the quarter. Fifth Third Bancorp owned about 0.16% of Verrica Pharmaceuticals worth $134,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals.

Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.